Liraglutide
Also known as: NN2211
A fatty-acylated GLP-1 analogue with a once-daily profile, approved as a medicine in multiple jurisdictions and extensively characterised in the literature.
Development status: Approved as a medicine in one or more jurisdictions
Identifiers and molecular characteristics
- CAS number
- Not verified
- Molecular formula
- Not verified
- Molecular mass
- Not verified
- Amino-acid sequence
- Not verified
- PubChem CID
- Not verified
Identifiers are published only with a source and a check date. Fields marked “not verified” have not yet been confirmed against a primary source — we show the gap rather than an unchecked figure. Always confirm against the certificate of analysis for the specific lot you hold.
Biological targets
- GLP-1 receptor
Mechanism of action
A single amino-acid substitution relative to human GLP-1 plus a palmitoyl side chain attached via a glutamate spacer. The side chain promotes albumin binding and self-association, slowing absorption and clearance.
Research evidence and its limits
Large phase 3 programme, cardiovascular outcome trial data and long post-approval experience.
Safety considerations
Approved product labelling from the relevant regulator is the authoritative source. Supplied and discussed here strictly as a laboratory research material. Not a medicine, not for human or veterinary administration, and nothing on this page should be read as a dosing, treatment or safety recommendation.
Analytical identification and quality testing
Mass spectrometry and RP-HPLC; the acylation is readily distinguished by mass from unmodified GLP-1.
Regulatory status
Approved in multiple jurisdictions. Confirm Indian status with CDSCO.
References
Related compounds
Semaglutide
A long-acting GLP-1 receptor agonist, structurally derived from human GLP-1 with modifications that resist enzymatic degradation and extend circulating half-life. Approved as a medicine in multiple jurisdictions.
Exenatide
A 39-residue peptide originally identified in the venom of the Gila monster, Heloderma suspectum, which acts as a GLP-1 receptor agonist. Historically important as the first incretin mimetic to reach the clinic.
Entry last reviewed 2026-10-11. Regulatory status and scientific understanding change; verify against primary sources before relying on anything here.